# 2025-14022: DEA proposes placing five obscure sedatives with names from a chemistry quiz

2025-14022, Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act, is a Federal Register proposed rule from Justice Department, Drug Enforcement Administration published 2025-07-25, effective Comments must be submitted on or before August 25, 2025. Temporary scheduling of these substances was set to expire July 26, 2025; DEA is publishing a temporary scheduling order elsewhere in this issue to extend temporary Schedule I status for one year, until July 26, 2026, or until the permanent scheduling action is completed, whichever occurs first.; PRIA reads it as touching household money (as of 2026-11-17).

- Canonical: https://policyrisk.com/federal-register/2025-14022
- As of: 2026-11-17
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-14022
- Title: Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
- Type: Proposed Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 35253
- Published: 2025-07-25
- Effective: Comments must be submitted on or before August 25, 2025. Temporary scheduling of these substances was set to expire July 26, 2025; DEA is publishing a temporary scheduling order elsewhere in this issue to extend temporary Schedule I status for one year, until July 26, 2026, or until the permanent scheduling action is completed, whichever occurs first.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-17

## In one line

DEA proposes placing five obscure sedatives with names from a chemistry quiz

## Summary

The DEA wants to make five substances—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—officially illegal by putting them in Schedule I, the strictest drug category. This means anyone making, selling, or using these drugs will face serious legal consequences. Comments on this plan are open until August 25, 2025, so speak up before then!

## Abstract

The Drug Enforcement Administration proposes placing clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam and their salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, as identified in this proposed rule, in schedule I of the Controlled Substances Act. These five substances were temporarily scheduled in an order dated July 26, 2023, and subsequently extended until July 26, 2026, pursuant to an extension published elsewhere in this issue of the Federal Register. This action will also enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would make permanent the existing regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle these five specific controlled substances.

## Effects PRIA read

- Permanent Schedule I listing and sanctions: cost, high. DEA proposes to permanently add clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam (and their salts and isomers) to Schedule I. If finalized, anyone who manufactures, distributes, imports, exports, researches, conducts instructional activities or chemical analysis with, or possesses…
- Mandatory DEA registration and controls for handlers: cost, low. If finalized, any person who handles these five substances must be registered with DEA and comply with Schedule I requirements including security rules, labeling and packaging rules, manufacturing quotas, initial and biennial inventories, records and reporting, order-form requirements, and import/e…
- Very small number of suppliers affected: benefit, low. DEA identified 10 entities supplying these substances (per the SciFinder database), of which 2 have already registered with DEA; DEA expects only 8 additional suppliers would be impacted. DEA estimates affected suppliers would account for about 0.73 percent of small entities in the smallest NAICS i…
- No accepted medical use in United States: cost, low. DEA (with HHS) states clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam are not approved by FDA and have no currently accepted medical use in treatment in the United States. HHS concluded these substances lack accepted safety for use under medical supervision.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22955](https://policyrisk.com/federal-register/2026-22955): Troy R. Lehman, D.O.; Decision and Order, 2026-11-12
- [2026-23006](https://policyrisk.com/federal-register/2026-23006): Importer of Controlled Substances Application: NSI Lab Solutions LLC, 2026-11-12

## Sources
- [2025-14022 on federalregister.gov](https://www.federalregister.gov/documents/2025/07/25/2025-14022/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and)
- [2025-14022 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-07-25/pdf/2025-14022.pdf)

## Related
- [Previous: 2025-14001, Amendment of Class D Airspace and Establishment of Class E2 Airspace Over Hampt…](https://policyrisk.com/federal-register/2025-14001)
- [Next: 2025-14060, Regulatory Publication and Review Under the Economic Growth and Regulatory Pape…](https://policyrisk.com/federal-register/2025-14060)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-14022 (as of 2026-11-17).
